Product Description
for the Second Line Treatment of Ovarian Cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00291837)
Mechanisms of Action: TOP1 Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: CTI BioPharma
Company Location: SEATTLE WA 98121
Company CEO: Adam R. Craig
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Ovarian Cancer|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00291785 |
CAM201 | P2 |
Completed |
Colorectal Cancer |
2007-08-01 |
2025-08-27 |
Primary Endpoints|Treatments |
|
NCT00291837 |
CAM203 | P2 |
Completed |
Ovarian Cancer |
2006-06-01 |
2019-03-21 |
||
2004-001457-28 |
2004-001457-28 | P2 |
Completed |
Ovarian Cancer |
None |
2022-03-12 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|